Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
ddEC-THP vs TCbHP in HER2-positive breast cancer
NCT05871918Phase 3Unknown
- Sponsor
- Tianjin Medical University Cancer Institute and Hospital
- Start
- Oct 2022
- Primary completion
- Dec 2023
- Modality
- Engineered Antibody Formats, Antibody Conjugates, Monoclonal Antibodies
- Countries
- 1
01
Overview
Phase 3, randomised, open-label trial of trastuzumab and pertuzumab in HER2-positive breast cancer, sponsored by Tianjin Medical University Cancer Institute and Hospital. Status: unknown.
02
Drugs
trastuzumabpertuzumab
03
Conditions
HER2-positive breast cancer
Beyond the preview
Go deeper on NCT05871918.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05871918.